Blue Orange

HEALTHCARE IT / RCM

SECTOR INTELLIGENCE REPORT

AI Data Optimization in Healthcare IT & Revenue Cycle Management

Transforming Revenue Capture, Compliance, and Care Delivery

Prepared for Operating Partners of Private Equity Firms
Blue Orange Digital | March 2026

March 2026

Table of Contents

Executive Summary

In November 2025, TowerBrook Capital Partners and Clayton, Dubilier & Rice closed the largest revenue cycle management acquisition in history: an $8.9 billion take-private of R1 RCM. The deal was not a bet on billing software. It was a thesis on what happens when artificial intelligence rewires the $4.3 trillion revenue engine that keeps American healthcare operational. Within weeks, Waystar followed with a $1.25 billion acquisition of Iodine Software, and Aspirion completed its fourth bolt-on in twelve months. The message from sophisticated capital was unambiguous: RCM is the next battleground for AI-driven value creation, and the window to build or buy a defensible position is closing fast.

The urgency is structural, not speculative. Global healthcare PE deal value hit a record $190 billion in 2025, with EBITDA multiples normalizing to 11 to 13 times after contracting from 14.5 times the prior year. That normalization created entry points. But the real catalyst sits deeper in the operating model: only 14% of healthcare providers currently use AI for denial management, prior authorization still consumes 13 physician hours per week, and the average health system bleeds $1.2 to $2.5 million annually in preventable revenue leakage. These are not projections. They are the current operating reality at the vast majority of portfolio companies in healthcare services.

This whitepaper examines how AI is reshaping Healthcare IT and Revenue Cycle Management through the lens of private equity value creation. It maps the production-ready deployments that are already generating measurable EBITDA impact, from ambient clinical documentation that adds $300,000 in annual revenue per physician to coding automation that cuts denial rates by 20 to 40 percent. It traces the regulatory architecture, including TEFCA mandates, ONC certification requirements, and HIPAA AI provisions, that is simultaneously creating compliance risk and platform consolidation opportunity. And it introduces Blue Orange Digital's AI Data Optimization Framework, a structured methodology for identifying, scoring, and sequencing the AI initiatives most likely to produce compounding returns across a healthcare IT portfolio.

The PE-Healthcare IT Landscape in 2026

Healthcare information technology has become the dominant deployment zone for private equity capital in the broader healthcare sector. The numbers tell a clear story: global healthcare PE deal value reached $190 billion in 2025, driven by lower interest rates, $880 billion in U.S.-based PE dry powder seeking deployment, and a normalization of valuations that turned compressed multiples into entry points rather than exit signals. Healthcare IT sits at the center of this capital rotation because it is the one subsector where AI can demonstrably move operating margins, not through speculative R&D bets but through production automation of the administrative processes that consume 30 cents of every healthcare dollar.

Valuations Have Reset: The Entry Window Is Open

The valuation environment in early 2026 favors buyers with operational playbooks. Healthcare services EBITDA multiples have settled at 11 to 13 times, down from the 14.5 times peak observed in 2024. Revenue multiples for RCM businesses specifically have moderated from 4.2 times in mid-2025 to 3.63 times by Q3, creating a spread that disciplined operators can exploit. The exception is specialized healthcare IT with demonstrated AI capabilities, where multiples remain elevated at 21.7 times EBITDA, a premium that underscores the market's conviction that AI-native platforms will capture disproportionate value in the consolidation cycle ahead.

Segment	Q3 2025 Multiple	Prior Period	Trend
Healthcare Services EV/EBITDA	11.5x	14.5x (2024)	Normalized
RCM Revenue Multiples	3.63x	4.2x (Q2 2025)	Moderating
RCM EBITDA Multiples	12.77x	16.02x (Q2 2025)	Down from peak
Healthcare IT (AI-specialized)	21.7x	Higher (2024)	Premium persists

The Consolidation Logic: Why RCM Is the Acquisition Target

The R1 RCM transaction illustrates the thesis. Since 2019, R1 has completed six acquisitions averaging $406 million per deal, including the $675 million Acclara Solutions acquisition in late 2023. The strategy is vertical integration: assembling the coding, billing, denial management, and patient access functions into a single AI-powered platform that can demonstrate measurable margin improvement to health system clients. TowerBrook and CD&R paid $8.9 billion because they see a business that, once fully automated, generates the kind of operating leverage that turns a 12 times entry multiple into an 18 times exit.

Waystar's $1.25 billion acquisition of Iodine Software follows the same logic from the technology side. Iodine's AI-driven clinical documentation improvement and coding accuracy tools plug directly into Waystar's payment platform, creating a closed loop from clinical encounter to reimbursement. Aspirion's four acquisitions in twelve months, spanning AI/ML capabilities, motor vehicle accident RCM, and general revenue cycle management, represent the roll-up variant of the same consolidation playbook. In each case, the acquirer is buying data moats and workflow integration points that become more defensible as AI capabilities compound.

What AI Actually Does in Healthcare Revenue Cycles

The healthcare revenue cycle is an assembly line of administrative decisions, each one a potential point of revenue leakage. A claim denied because a code was wrong. A prior authorization delayed because a fax sat in a queue. A charge missed because documentation did not capture the clinical complexity of the encounter. AI's impact on this assembly line is not theoretical. It is measurable, production-grade, and already generating returns at health systems that have moved past the pilot stage.

Denial Management: The $1.2 Million Problem Hiding in Plain Sight

Only 14% of healthcare providers currently use AI for denial reduction. That statistic, from Combine Health's 2026 industry survey, represents one of the largest addressable inefficiencies in any PE-backed service business. The median health system experiences denial rates between 5 and 15 percent of submitted claims, and the cost of reworking a denied claim runs $25 to $118 per claim depending on complexity. For a mid-size health system processing 500,000 claims annually, even a modest denial rate translates to tens of millions in delayed or lost revenue.

AI denial management works by analyzing patterns across historical claims data, payer-specific denial reasons, and clinical documentation to predict which claims will be denied before submission. A regional behavioral health network serving 12,000 patients annually deployed automated billing management with AI denial detection and realized $1.2 million in annual cost savings through reduced staffing needs and a 95% reduction in prior authorization processing time. Another health system reported a 30% reduction in accounts receivable days within one quarter, unlocking $2.5 million in previously trapped cash flow. A third deployment caught and recouped nearly $200,000 in missed denials through pattern analysis that human reviewers had overlooked.

The economics are straightforward. Comprehensive AI RCM solutions cost $500 to $2,000 per provider monthly. Against annual revenue leakage measured in millions, the return on investment typically materializes within six to twelve months. The remaining 86% of providers who have not yet adopted AI denial management represent the single largest near-term value creation opportunity in healthcare IT.

Prior Authorization: From Days to Minutes

Prior authorization is the administrative process that physicians hate most, and for good reason. The average provider spends 13 hours per week navigating prior authorization requirements, a burden that translates directly to reduced patient throughput and physician burnout. The American Medical Association has documented that 94% of physicians report prior authorization negatively impacts clinical outcomes. Into this dysfunction, AI is injecting genuine speed.

Optum's InterQual Auth Accelerator has demonstrated a 56% reduction in review time with 45% fewer manual touches and an 80% improvement in processing efficiency. Montage Health reported a 22% reduction in Epic authorization work queue volume after deploying AI-assisted workflows. Multi-agent AI solutions are compressing prior authorization processing from days to minutes, with some workflows completing in under ten minutes. Humata Health deployments have achieved 96% first-pass approval rates, and across markets, 75% of health plans now report using AI for prior authorization approvals.

The caveat matters: limited public data exists on whether AI-accelerated prior authorization produces better or worse clinical outcomes than manual review. The speed gains are real and measurable; the clinical safety implications require ongoing monitoring. For PE operating partners, this means prior authorization automation should be deployed with governance frameworks that track not just efficiency metrics but downstream clinical indicators.

Medical Coding: The Accuracy Multiplier

AI-driven hybrid coding models are achieving up to 99% accuracy in production environments, delivering a 50% reduction in coding-related denials and a 30% reduction in coding costs once fully integrated. The operational improvements are equally significant: 30 to 70% reduction in coding workload, 50% faster coding cycles, and 20 to 40% reduction in denial rates after integration.

The emerging frontier is agentic AI coding, where the system operates as an autonomous employee rather than a suggestion engine. These systems review charts, extract clinical details, assign codes with explanations, and flag complex cases for human oversight. Point-of-care coding, where code previews appear at the clinician workstation before the encounter reaches the RCM queue, is becoming the standard architecture for 2026 deployments. The hybrid human-AI model, where AI handles routine high-volume work while human coders focus on oversight, compliance, and exceptions, is the production configuration that sophisticated operators are converging on.

Clinical Documentation AI: The Productivity Revolution That Needs Nuance

Ambient clinical documentation has crossed the adoption threshold. According to a comprehensive survey of 2,784 Epic EHR system users across 1,744 hospitals, 62% of U.S. hospitals have adopted an ambient AI documentation tool, with DAX Copilot, Abridge, and ThinkAndor commanding more than 80% of the adopter market. Epic fully embedded DAX Copilot in January 2026, and Meditech announced Expanse EHR integration in March 2026. The infrastructure is in place. The question now is whether the productivity gains justify the investment thesis.

The Revenue Math: $300,000 Per Physician, Per Year

The headline number is striking. Physicians using ambient AI documentation tools are generating a 5.8% relative increase in weekly RVUs and a 2.8% increase in encounters per week. At 2025 Medicare rates, that translates to approximately $300,000 in additional annual revenue per physician. For a health system with 200 physicians, the aggregate revenue impact approaches $60 million annually, a number that fundamentally changes the EBITDA trajectory of a PE-backed healthcare platform.

Mass General Brigham's ambient scribe pilot documented a 40% relative drop in self-reported documentation burden burnout, a metric that matters because physician attrition costs between $500,000 and $1 million per departure when recruiting, onboarding, and lost revenue are factored in. The productivity gains are real, but they compound with retention effects that are harder to quantify but equally material.

The Uncomfortable Reality: Efficiency Gains Are Not Universal

Northwestern Medicine's one-year longitudinal study, published in NEJM AI, tells a more nuanced story. After making DAX Copilot available across its system, with adoption reaching at least 50% of patient encounters, the institution found that ambient AI did not increase overall clinician efficiency as a group. High DAX users experienced approximately a 7% reduction in documentation hours compared to the control group, but the aggregate effect was muted.

This finding matters for PE operators because it suggests that ambient documentation AI is not a deploy-and-forget productivity tool. The variance in outcomes across clinicians means that deployment strategies must include change management, workflow redesign, and targeted training to realize the full revenue potential. The health systems that capture the $300,000-per-physician upside are those that pair the technology with operational discipline, the exact competency that differentiates strong PE operators from passive capital.

Geographic and Institutional Whitespace

Adoption patterns reveal significant remaining opportunity. Larger hospitals, metropolitan locations, nonprofits, and systems with stronger operating margins show higher adoption rates. The Midwest lags behind the South in uptake. Smaller hospitals and rural or critical access facilities represent largely untapped markets. For PE portfolio companies with multi-site healthcare operations, the ambient documentation rollout playbook is geographic expansion into laggard regions, starting with surgical specialties where the documentation burden is highest and the RVU uplift is most immediate.

The Regulatory Architecture: Compliance as Competitive Advantage

05

Healthcare IT regulation in 2026 is not merely a compliance burden. It is an architectural force reshaping which platforms survive and which become acquisition targets. Three regulatory streams converge this year, and their intersection creates both risk and opportunity for PE-backed healthcare IT companies.

TEFCA and CMS Interoperability: The July 4 Deadline

The Trusted Exchange Framework and Common Agreement has reached critical mass. As of January 1, 2026, state Medicaid managed care plans, CHIP entities, Medicare Advantage plans, and ACA exchange plans must all expose FHIR-based APIs for patient access and provider data exchange. The harder deadline arrives on July 4, 2026, when all federally-funded healthcare entities must participate in nationwide health information exchange via modern FHIR APIs aligned with US Core Implementation Guide and USCDI v3 standards.

For PE operating partners, this deadline is a platform consolidation catalyst. FHIR and TEFCA create network effects that favor integrated platforms over point solutions. Smaller vendors face integration cost pressures they cannot absorb independently, creating acquisition opportunities for capitalized buyers. The companies that have already built FHIR-native architectures will command premium multiples at exit; those that have not will face remediation costs that compress margins and extend timelines.

ONC Certification: AI Transparency Is Now Mandatory

The HTI-1 certification updates represent the first time certified health IT products using AI or ML must meet explicit transparency requirements. Products must identify where AI is embedded, disclose how it works, and document algorithmic risk profiles including bias assessment, governance controls, mitigation strategies, and performance monitoring. Safety and performance standards now require certified systems to prove safe AI integration with seamless FHIR/SMART-based data exchange capability.

This is not a theoretical standard sitting in a comment period. It is the law. Portfolio companies deploying AI in clinical workflows must either build these transparency and governance capabilities in-house or source them from vendors who can demonstrate certified compliance. The practical effect is to raise the barrier to entry for AI in healthcare, which benefits established platforms and creates a moat around companies that have invested in governance infrastructure.

HIPAA in the Age of AI: Six-Year Audit Trails

HIPAA's updated provisions clarify that AI decisions touching protected health information require six-year audit log retention with full traceability of decision pathways. The distinction between AI inference and model training under PHI use rules is now explicit: different activities require different compliance frameworks. All AI-generated outputs influencing PHI decisions must have human oversight, and business associate agreements now require AI-specific clauses covering vendor transparency and regular algorithmic audits.

Sixty percent of healthcare organizations plan to establish formal AI governance programs by 2026, driven by these requirements. For PE portfolio companies, HIPAA compliance in an AI context is no longer a checkbox exercise. It requires purpose-built data infrastructure, audit logging systems, and governance workflows that are expensive to retrofit but relatively inexpensive to build into new deployments. This asymmetry between greenfield and brownfield compliance costs is another driver of the consolidation thesis.

The Change Healthcare Lesson: Cybersecurity as Material Business Risk

In February 2024, the ALPHV/BlackCat ransomware group breached Change Healthcare in what became the largest healthcare data breach in U.S. history, affecting 192.7 million individuals. UnitedHealth Group paid a $22 million ransom, a sum that proved insufficient for operational recovery. The breach disrupted claims processing across the entire industry, forced manual claims submission at thousands of organizations, interrupted pharmacy transactions, and created reconciliation burdens that persisted through multiple billing cycles.

The Change Healthcare breach is the single most important data point for PE operating partners evaluating healthcare IT investments in 2026. It demonstrated that cybersecurity is not an IT department concern but a material business risk that can destroy enterprise value overnight. Ransomware attacks against healthcare surged 36% year-over-year in late 2025, with average breach costs reaching approximately $10 million per incident. Healthcare now faces more than one-third of all ransomware attacks globally.

Portfolio Construction Implications

The lessons for PE portfolio construction are specific and actionable. Single points of failure in healthcare IT infrastructure create systemic risk that no amount of insurance can fully mitigate. Diversified claims processing pathways are now table stakes for any platform handling reimbursement workflows. Distributed cloud-native architectures are inherently more resilient than monolithic on-premise systems. And the litigation tail risk, Change Healthcare and UnitedHealth Group still face consolidated lawsuits with unclear recovery timelines, means that cybersecurity due diligence must be as rigorous as financial due diligence.

For portfolio companies already in the fold, the action items are immediate: geographic redundancy for critical systems, quarterly tabletop incident response exercises, enhanced cyber insurance with coverage limits scaled to revenue exposure, and contractual liability allocation with third-party vendors. The cost of these measures is a fraction of the value destruction that a successful attack can inflict.

The State of Clinical AI: What the Models Can and Cannot Do

07

The conversation about AI in healthcare often conflates benchmark performance with production capability. A rigorous assessment of where clinical AI actually stands is essential for PE operators calibrating their investment timelines.

Medical Reasoning: Promising but Below Physician Level

The most comprehensive assessment of LLM clinical reasoning, published in NEJM AI, evaluated leading models on both fixed clinical vignettes and structural clinical tasks. On standard medical multiple-choice examinations, LLMs matched or exceeded medical student performance. The top performer, OpenAI's o3, achieved 67.8% accuracy on clinical reasoning assessments, followed by GPT-4o at 63.9%. Neither reached the performance levels of senior residents or attending physicians.

More telling was the performance gap between controlled assessments and real-world clinical tasks. When models were asked to perform structural clinical work, retrieving patient data from EHRs, ordering appropriate tests, prescribing medications, performance dropped markedly. Stanford and Harvard are developing new benchmarks that evaluate AI agents on actual EHR tasks, acknowledging that curated clinical vignettes overstate production readiness. Reasoning-tuned models also exhibit systematic overconfidence, rarely expressing uncertainty, a characteristic that is problematic in clinical contexts where knowing what you do not know is a core competency.

What This Means for Healthcare IT Investment

The clinical AI performance data has a direct implication for PE thesis development. AI is production-ready for administrative and operational healthcare tasks: coding, billing, denial management, scheduling, prior authorization, and clinical documentation capture. These are pattern-matching and workflow automation problems where current model capabilities deliver measurable ROI. AI is not yet production-ready for autonomous clinical decision-making, and investments predicated on that assumption carry execution risk.

The actionable insight is to invest in the administrative automation layer, where model capabilities already exceed the threshold for value creation, while monitoring the clinical reasoning frontier for the next wave of deployment opportunities. Open-source medical LLMs with privacy-preserving on-device deployment options are maturing rapidly, and the gap between benchmark performance and production capability is narrowing with each model generation.

Production Deployments: Case Studies with Measurable ROI

The difference between AI hype and AI value is measured in operating results. The following deployments represent the current frontier of production healthcare AI, each with quantified outcomes that PE operating partners can use to benchmark portfolio company opportunities.

Cleveland Clinic: Sepsis Detection That Actually Works

Cleveland Clinic deployed an AI-driven sepsis detection alert system that achieved a 10-fold reduction in false positives compared to the previous rule-based system, a 46% increase in identified sepsis cases, and a 7-fold increase in cases alerted before antibiotic administration. The clinical significance is substantial: sepsis kills more than 350,000 Americans annually and is the most expensive condition treated in U.S. hospitals. Reducing false positives is as important as increasing true positives, because alert fatigue from false alarms is one of the primary reasons clinicians ignore sepsis warnings.

Mount Sinai: $20 Million from Malnutrition Detection

Mount Sinai Health System developed an internal AI tool for inpatient malnutrition detection that generates approximately $20 million in annual revenue impact. The mechanism is improved coding capture: malnutrition is a common comorbidity that is systematically under-documented and under-coded, resulting in missed billing opportunities and inaccurate risk adjustment scores. The AI tool analyzes clinical documentation in real time, flags likely malnutrition cases, and prompts clinicians to document appropriately. The revenue impact comes from correct coding on claims that were previously submitted at lower reimbursement levels.

Mass General Brigham: Burnout Reduction as Revenue Protection

Mass General Brigham's ambient scribe pilot demonstrated a 40% relative reduction in self-reported documentation burnout. While burnout is often discussed as a quality-of-life issue, it has direct financial implications: burned-out physicians reduce their clinical hours, leave practices earlier, and generate less revenue per FTE. A 40% reduction in the primary driver of physician dissatisfaction is a retention tool with quantifiable economics, particularly in an environment where replacing a single physician costs $500,000 to $1 million.

The Aggregate Picture

Across health systems reporting AI outcomes, 85% of executives report increased revenue and 80% report reduced costs from AI deployments. The collective impact across reporting institutions amounts to hundreds of lives saved and more than $100 million in annual cost reduction. AI-enabled healthcare startups captured 62% of all digital health venture funding in the first half of 2025, with average round sizes of $34.4 million, signaling that the investment community has moved past the question of whether healthcare AI works and onto the question of which platforms will capture the most value.

Health System	AI Deployment	Key Metric	Financial Impact
Cleveland Clinic	Sepsis detection AI	10x fewer false positives	Reduced sepsis mortality
Mount Sinai	Malnutrition detection	Coding capture improvement	~$20M annual revenue
Mass General Brigham	Ambient scribe pilot	40% burnout reduction	Retention economics
Regional BH Network	AI denial management	95% PA time reduction	$1.2M annual savings
Aggregate (industry)	Multiple AI deployments	85% report revenue lift	$100M+ cost reduction

The EBITDA Expansion Playbook for Healthcare IT

Translating AI capabilities into EBITDA impact requires a structured approach that sequences initiatives by payback period, implementation complexity, and data readiness. The following framework maps the primary value creation levers available to PE operating partners managing healthcare IT portfolio companies in 2026.

The Margin Expansion Pathway

Value Lever	Baseline Margin	AI-Enhanced Target	Expansion	Timeline	Penetration
Denial Management	18%	22-24%	+4-6pp	12-18 mo	14% adopted
Prior Auth Automation	20%	23-25%	+3-5pp	6-12 mo	75% payer-side
Ambient Documentation	22%	25-27%	+3-5pp	12-18 mo	62% hospitals
Coding Optimization	19%	23-25%	+4-6pp	12-24 mo	Low adoption
Staffing Efficiency	16%	20-22%	+4-6pp	18-24 mo	Emerging
Combined Effect	18%	26-30%	+8-12pp	24-30 mo	

Sequencing: What to Deploy First

The optimal deployment sequence starts with denial management automation, where the 86% of providers who have not yet adopted AI represent the widest addressable gap and the payback period is 6 to 12 months. Prior authorization automation follows as a parallel workstream, delivering immediate workflow improvement and physician satisfaction gains that support retention. Ambient clinical documentation deploys in Phase 2, targeting high-RVU specialties first to maximize the revenue-per-physician uplift. Coding optimization and staffing efficiency improvements layer on top of the data infrastructure built during Phases 1 and 2.

The Multiple Expansion Math

At current entry multiples of 11 to 13 times EBITDA, a healthcare IT platform that achieves an 8 to 12 percentage point margin expansion through AI deployment can generate significant multiple expansion at exit. AI-enhanced healthcare IT platforms with demonstrated margin improvement are commanding 14 to 16 times EBITDA at exit, representing 3 to 5 turns of multiple expansion from the combination of margin improvement and premium re-rating. On a $200 million revenue platform with $36 million in baseline EBITDA at 18% margins, expanding margins to 28% produces $56 million in EBITDA. The difference between a 12 times entry and a 15 times exit on that EBITDA trajectory is the difference between a 2.3 times and a 3.7 times return on invested capital.

Blue Orange Digital's AI Data Optimization Framework

Blue Orange Digital has developed a structured methodology for identifying, scoring, and sequencing AI initiatives across healthcare IT portfolio companies. The framework addresses the central challenge PE operators face: not whether AI can create value in healthcare, but which specific deployments will generate the highest risk-adjusted returns given each portfolio company's data maturity, regulatory position, and competitive dynamics.

The Composite Priority Score

Every AI initiative is evaluated using a composite score that balances potential EBITDA impact against implementation feasibility:

Score = ((EBITDA Low + EBITDA High) / 2) x Portfolio Multiplier / (Data Readiness x Implementation Complexity x (Time to Value / 12))

EBITDA Impact captures the expected margin improvement range. Portfolio Multiplier reflects the number of portfolio companies where the initiative can be replicated, creating compounding returns across a fund's healthcare holdings. Data Readiness assesses whether the required data infrastructure exists or must be built. Implementation Complexity accounts for integration requirements, change management needs, and regulatory considerations. Time to Value penalizes initiatives with long payback periods.

Healthcare IT Use Case Library

The framework includes a scored library of 30+ healthcare-specific AI use cases spanning RCM automation, clinical documentation, population health analytics, cybersecurity hardening, and interoperability compliance. Each use case is mapped to specific EBITDA impact ranges, data requirements, regulatory dependencies, and implementation timelines derived from production deployments at health systems and healthcare IT companies.

Phased Deployment Roadmap

The framework organizes deployment into three phases. Phase 1 targets quick wins with high data readiness and immediate EBITDA impact: denial management automation, prior authorization workflows, and basic coding assistance. Phase 2 expands into productivity multipliers that require integration with existing clinical systems: ambient documentation, value-based care analytics, and risk adjustment optimization. Phase 3 tackles strategic initiatives that build long-term competitive moats: AI-native platform architecture, TEFCA-compliant data exchange, and predictive population health models that position portfolio companies for premium exit multiples.

Conclusion: The 24-Month Window

Healthcare IT in 2026 presents a convergence of conditions that PE operators encounter rarely: normalized entry valuations, production-ready AI capabilities with demonstrated ROI, regulatory catalysts that drive platform consolidation, and a vast installed base of providers that have not yet adopted automation for their most expensive administrative processes. The R1 RCM transaction set the valuation benchmark. The TEFCA deadline creates urgency. The data from Cleveland Clinic, Mount Sinai, Mass General Brigham, and dozens of other health systems provides the evidence base.

The window is approximately 24 months. By 2028, the providers who adopted AI for denial management, prior authorization, and clinical documentation in 2026 and 2027 will have compounded two to three years of margin improvement. Their EBITDA trajectories will reflect not just the direct savings from automation but the second-order effects: better physician retention, more accurate coding, faster cash conversion cycles, and the operational data that makes each subsequent AI deployment more effective. The health systems and IT platforms that delayed will face higher implementation costs, scarcer talent, and the competitive disadvantage of operating with 2023-era margins in a 2028 market.

Blue Orange Digital's AI Data Optimization Framework provides the structured methodology to move quickly and deliberately. It transforms the question from 'should we invest in AI' to 'which AI initiatives, in which sequence, will generate the highest compounding returns across our healthcare portfolio.' For PE operating partners managing healthcare IT assets, that is the only question that matters.

Ready to Accelerate AI Value Creation?

Blue Orange Digital partners with PE operating teams and portfolio companies to design, build, and scale AI data systems that deliver measurable EBITDA impact.

blueorange.digital | **hello@blueorange.digital**

About Blue Orange Digital

Blue Orange Digital is a data engineering and AI consultancy specializing in building production-grade AI systems for private equity-backed companies. We combine deep vertical expertise with proven technical frameworks to accelerate value creation across the portfolio.

New York | Washington DC | **blueorange.digital**